Press release

Medivir 2022 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the company’s website:

Medivir's cutting edge project fostrox has the potential to become the first liver-targeted, orally administered drug to help patients with various cancers of the liver, an area of great medical need. The clinical development of fostrox has been in focus in 2022 with a high recruitment rate in the second half of the year, which enabled the phase 2a part of the study, with fostrox in combination with Lenvima®, to start at the beginning of 2023. Interest in the study remains very high.


Several of the company's out-licensed projects have developed in a very positive direction during 2022 and are moving towards an exciting future. For two of these projects, clinical development programs are likely to be initiated in 2023.


This and much more can be found in Medivir's Annual Report 2022, published today at the website;



For additional information, please contact

Magnus Christensen, CFO

Telephone: +46 8 5468 3100






Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list.